In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature program, an innovative approach ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

*AA Signature, by Allergan Aesthetics, is a new program that is launching Internationally at the IMCAS congress in Paris and will be considered for roll out across International markets, as ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global expansion with Cartistem, its allogeneic human umbilical cord blood-derived ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several ... has gained exclusive commercial rights in the U.S. and Canada to Kloxxado, an emergency nasal spray for opioid ...

AbbVie will receive royalties on net sales within Greater China. Credit: © AbbVie Inc. All rights reserved. AbbVie and Simcere Zaiming have announced an option-to ...

In return, Bausch Health is granted a license to exclusively commercialize GMRx2, supplied by George Medicines, in Canada, Mexico, Columbia and Central America. Bausch Health is responsible for ...

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. today announced an option to license agreement to develop SIM0500, an investigational new drug candidate.